Key result
Enzyme replacement therapy is linked to ~26 percentage points fewer cases of concordant adverse cardiac remodeling.
Why the study?
Fabry cardiomyopathy involves structural hypertrophy, mechanical dysfunction, and electrical conduction abnormalities that often evolve asynchronously. It remained unclear whether enzyme replacement therapy modifies multidomain longitudinal remodeling patterns rather than isolated parameters.
Does enzyme replacement therapy (ERT) modify multidomain longitudinal structural, mechanical, and electrical remodeling trajectories in patients with genetically confirmed Fabry cardiomyopathy?
Cohort (n=38)
Yes
Does enzyme replacement therapy (ERT) modify multidomain longitudinal structural, mechanical, and electrical remodeling trajectories in patients with genetically confirmed Fabry cardiomyopathy?
In Fabry cardiomyopathy, enzyme replacement therapy is associated with a redistribution of longitudinal electrical and mechanical remodeling trajectories rather than uniform structural and functional recovery, supporting a multidomain trajectory-based assessment framework.
ERT may redistribute remodeling phenotypes in Fabry cardiomyopathy; leaves open effects on outcomes or need for trajectory-based monitoring.
Background Fabry cardiomyopathy involves structural hypertrophy, mechanical dysfunction, and electrical conduction abnormalities that often evolve asynchronously. Whether enzyme replacement therapy (ERT) modifies multidomain longitudinal remodeling patterns rather than isolated parameters remains unclear. Methods We performed a multicenter retrospective longitudinal study of 38 patients with genetically confirmed Fabry disease, with paired baseline and follow-up evaluations over a median of 5.3 years (IQR 2.8–7.1). Structural remodeling was indexed by left ventricular mass index (LVMi), mechanical remodeling by left ventricular global longitudinal strain (LVGLS), and electrical remodeling by QRS duration on 12-lead ECG. Echocardiographic measurements were quantified using an AI-assisted deep learning platform to ensure standardized longitudinal analysis. Within-patient directional changes were classified as adverse or non-adverse according to domain-specific clinical meaning, and electrical–mechanical remodeling phenotypes were constructed. Results Electrical remodeling showed significant longitudinal progression, with QRS duration increasing from 131.11 ± 34.07 ms to 138.22 ± 36.30 ms (Δ +7.11 ms, 95% CI 0.68–13.53; p=0.031). Mechanical remodeling demonstrated a trend toward improved deformation, with LVGLS changing from −14.74 ± 5.83% to −16.69 ± 4.44% (Δ −1.95%, 95% CI −4.05 to 0.14; p=0.067). Structural remodeling remained stable, with LVMi changing from 177.35 ± 74.48 to 181.67 ± 73.92 g/m² (Δ +4.32 g/m²; p=0.413). Based on combined directional changes in QRS and LVGLS, four electrical–mechanical phenotypes were identified: concordant adverse (n=18, 47.4%), electrical-leading adverse (n=12, 31.6%), mechanical-leading adverse (n=5, 13.2%), and concordant favorable (n=3, 7.9%). Untreated patients were predominantly characterized by concordant adverse remodeling (81%), whereas ERT-treated patients exhibited redistribution toward electrical-leading remodeling (55%) and exclusive occurrence of concordant favorable remodeling (p<0.001 for distribution difference). Conclusions Fabry cardiomyopathy is characterized by frequent multidomain, non-parallel remodeling over long-term follow-up. ERT does not produce uniform structural and functional recovery but is associated with a redistribution of longitudinal remodeling trajectories across domains. These findings challenge the assumption of parallel disease progression and support a trajectory-based framework for longitudinal assessment in Fabry cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Sung et al. (2026) conducted a cohort in Fabry cardiomyopathy (n=38). Enzyme replacement therapy (ERT) vs. Untreated patients was evaluated on Distribution of electrical-mechanical remodeling phenotypes (specifically electrical-leading vs concordant adverse remodeling) (p=<0.001). Enzyme replacement therapy shifted remodeling from concordant adverse (81% untreated) toward electrical-leading phenotypes (55% treated; p<0.001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: